HEP DART 2019: Frontiers in Drug Development for Hepatology

摘要/项目摘要： HEP DART：肝病药物开发前沿是一个每两年一次的独立会议 过去 24 年来吸引了至少 250 名与会者。 HEP DART 向任何感兴趣的人开放 病毒性肝炎和慢性肝病的治疗。本次会议的内容被制定为 主要感兴趣的是科学家和临床研究人员，重点关注药物开发和 疫苗学。 HEP DART 2019 的目的是聚集临床医生、研究人员、基础科学家、护士 和医师助理一起提高我们对正在进行的药物开发的了解 病毒性肝炎（HBV、HCV、HDV、HAV 和 HEV）、非酒精性肝炎的治疗过程 脂肪性肝炎（NASH）和肝细胞癌（HCC）。 HEP DART 将独特地融合 生物学、化学、药理学和临床研究领域为科学界提供 随着对肝脏感染治疗当前和未来挑战的更多了解， 疾病和癌症。目标：(1) 突出抗病毒性肝炎药物开发的进展 如乙型肝炎病毒、丙型肝炎病毒和丁型肝炎病毒。 (2)描述乙型肝炎治疗策略的最新进展。 (3) 重点介绍针对 NASH、纤维化和 HCC 的药物开发进展。 (4)描述小说 病毒性肝炎、肝病和治疗结果的生物标志物。 (5) 回顾目前的治疗方法并 病毒性肝炎疫苗接种指南；描述改进治疗方案的进展。 (6) 了解 HBV 感染和 NASH 对儿科和青少年群体的影响。 (7) 评估疫苗和治疗性疫苗在病毒性肝炎、NASH 和 NASH 未来治疗中的作用 HIV合并感染。 （8）了解HDV、HAV、HEV的流行病学和发病机制。 方法：HEP DART 2019 包括四天的科学演讲，以口头形式进行 通过非并发会话的海报演示格式。埃默里大学办公室 继续医学教育指定 HEP DART 可获得最多 24 个 1 类学分 AMA 医师认可奖。 HEP DART 提供轻松且科学的刺激 为博士和医学博士提供交流和共同学习的氛围。请求支持以帮助支付费用 为年轻研究者、妇女、有色人种和其他群体提供奖学金和旅费补助的费用 代表人数不足。

Abstract/ Project summary: HEP DART: Frontiers in Drug Development for Hepatology is an independent biennial conference attracting at least 250 attendees for the past 24 years. HEP DART is open to anyone interested in therapies for viral hepatitis and chronic liver disease. The content of this conference was developed to interest primarily scientists and clinical researchers with a focus on drug development and vaccinology. The aim of HEP DART 2019 is to assemble clinicians, researchers, basic scientists, nurses and physician assistants together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non‐‐‐alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). HEP DART will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for liver infection, disease and cancer. OBJECTIVES: (1) Highlight advances in drug development against viral hepatitis such as HBV, HCV, and HDV. (2) Describe the latest developments in HBV curative strategies. (3) Highlight advances in drug development against NASH, fibrosis and HCC. (4) Describe novel biomarkers for viral hepatitis, liver disease, and treatment outcomes. (5) Review current treatment and vaccination guidelines for viral hepatitis; describe advancements in improved treatment regimens. (6) Understand the consequences of HBV infection and NASH in pediatrics and adolescent populations. (7) Assess the role of vaccines and therapeutic vaccines in future therapies for viral hepatitis, NASH, and co‐‐‐infections with HIV. (8) Understand the epidemiology and pathogenesis of HDV, HAV and HEV. METHODS: HEP DART 2019 comprises four days of scientific presentations, delivered in both oral and poster presentations formats via non‐‐‐concurrent sessions. Emory University, Office of Continuing Medical Education designates HEP DART for a maximum 24 category 1 credits toward the AMA Physician’s Recognition Award. HEP DART provides a relaxed and scientifically stimulating atmosphere for both PhDs and MDs to network and learn together. Support is requested to help defray costs of scholarships and travel grants for young investigators, women, visible minorities and other under‐‐‐represented delegates.